STOCKHOLM, Nov. 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has been launched in Japan for the treatment of early Alzheimer's disease. Japan is the second country,...
Hence then, the article about leqembi pen subcutaneous treatment launched in japan was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Leqembi® Pen subcutaneous treatment launched in Japan )
Also on site :
- Nvidia’s Jensen Huang was the Jenga piece to a towering multi-trillion AI industry. Will his exit set off a chain reaction?
- ‘The Amazing Race’s Michelle and Matt Patterson Reveal the Surprising Team They Tried to Form an Alliance With (Exclusive)
- Documentaries at the Oscars: A History of Breaking Out of Their Category — and What It Means for ‘You Can See Everything’